SynthesisBMC infectious diseases2017
Diagnostic accuracy of tests to detect Hepatitis C antibody: a meta-analysis and review of the literature.
Synthesis in BMC infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Population-Based Testing for Undiagnosed Hepatitis C: A Systematic Review of Economic Evaluations.Applied health economics and health policy · 2022Pooled it
- Persistently high hepatitis C rates in haemodialysis patients in Brazil [a systematic review and meta-analysis].Scientific reports · 2022Pooled it
- Diagnostic accuracy of serological diagnosis of hepatitis C and B using dried blood spot samples (DBS): two systematic reviews and meta-analyses.BMC infectious diseases · 2017Pooled it
- Bundling Rapid Human Immunodeficiency Virus and Hepatitis C Virus Testing to Increase Receipt of Test Results: A Randomized Trial.Medical care · 2020Trial
- Trial
- Development and Characterization of Dual-Platform Lyophilized Plasma-Based Quality Control Materials for Hepatitis C Virus Antibody Testing.Diagnostics (Basel, Switzerland) · 2026Article
- Cost-Effectiveness of Point-of-Care Hepatitis C Virus RNA Testing in the US.JAMA network open · 2026Article
- 2025 KASL clinical practice guidelines for management of hepatitis C.Clinical and molecular hepatology · 2026Article
- Hepatitis C Screening: A Health Technology Assessment.Ontario health technology assessment series · 2026Article
- Philippine Clinical Practice Guidelines for Periodic Health Examination: Screening for Infectious Diseases.Acta medica Philippina · 2026Article
- Evaluating performance of the Bioline™ HCV point-of-care test in Ghana.BMC infectious diseases · 2025Article
- Linkage to hepatitis C virus care in a binational cohort study of People who inject drugs on the U.S.-Mexico border.The International journal on drug policy · 2025Article
- A scoping review on HCV screening strategies: population to screen and the test types.BMC public health · 2025Article
- Cost-Effectiveness of Screening and Treating Chronic Hepatitis C Virus Infection in Zimbabwe.International journal of environmental research and public health · 2025Article
- Predictors of Acute HCV Incidence in People with HIV: Insights from a Long-term Cohort Study.Journal of acquired immune deficiency syndromes (1999) · 2025Article
- Seroprevalence and Predictors of Hepatitis B and C Virus Infections Among Patients with Chronic Liver Diseases in Dodoma Region, Tanzania: A Cross-Sectional Study.Hepatic medicine : evidence and research · 2025Article
- REVIRAL: roadmap for the elimination of viral hepatitis in Latin America.Frontiers in public health · 2025Article
- Self-testing strategy to eliminate hepatitis C as per World Health Organization's goal: Analysis of disease burden and cost-effectiveness.Clinical and molecular hepatology · 2025Article
- Elimination of HCV Infection: Recent Epidemiological Findings, Barriers, and Strategies for the Coming Years.Viruses · 2024Review
- The Pre-/Post-Transplant Hepatitis C Antibody Associated with the IL-28B RS8099917 TT Genotype and miRNA-122 Expression May Protect Acute Cellular Rejection After LDLT.Current issues in molecular biology · 2024Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundAlthough direct-acting antivirals can achieve sustained virological response rates greater than 90% in Hepatitis C Virus (HCV) infected persons, at present the majority of HCV-infected individuals remain undiagnosed and therefore untreated. While there are a wide range of HCV serological tests available, there is a lack of formal assessment of their diagnostic performance. We undertook a systematic review and meta-analysis to evaluate he diagnostic accuracy of available rapid diagnostic tests (RDT) and laboratory based EIA assays in detecting antibodies to HCV.
methodsWe used the PRISMA checklist and Cochrane guidance to develop our search protocol. The search strategy was registered in PROSPERO (CRD42015023567). The search focused on hepatitis C, diagnostic tests, and diagnostic accuracy within eight databases (MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, Science Citation Index Expanded, Conference Proceedings Citation Index-Science, SCOPUS, Literatura Latino-Americana e do Caribe em Ciências da Saúde and WHO Global Index Medicus. Studies were included if they evaluated an assay to determine the sensitivity and specificity of HCV antibody (HCV Ab) in humans. Two reviewers independently extracted data and performed a quality assessment of the studies using the QUADAS tool. We pooled test estimates using the DerSimonian-Laird method, by using the software R and RevMan. 5.3.
resultsA total of 52 studies were identified that included 52,673 unique test measurements. Based on five studies, the pooled sensitivity and specificity of HCV Ab rapid diagnostic tests (RDTs) were 98% (95% CI 98-100%) and 100% (95% CI 100-100%) compared to an enzyme immunoassay (EIA) reference standard. High HCV Ab RDTs sensitivity and specificity were observed across screening populations (general population, high risk populations, and hospital patients) using different reference standards (EIA, nucleic acid testing, immunoblot). There were insufficient studies to undertake subanalyses based on HIV co-infection. Oral HCV Ab RDTs also had excellent sensitivity and specificity compared to blood reference tests, respectively at 94% (95% CI 93-96%) and 100% (95% CI 100-100%). Among studies that assessed individual oral RDTs, the eight studies revealed that OraQuick ADVANCE® had a slightly higher sensitivity (98%, 95% CI 97-98%) compared to the other oral brands (pooled sensitivity: 88%, 95% CI 84-92%).
conclusionsRDTs, including oral tests, have excellent sensitivity and specificity compared to laboratory-based methods for HCV antibody detection across a wide range of settings. Oral HCV Ab RDTs had good sensitivity and specificity compared to blood reference standards.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.